Rhovac board member resigns due to health reasons
LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons. Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I w...
RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
STOCKHOLM, May 30, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today onMay 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (on...
Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers
STOCKHOLM, May 19, 2022 /PRNewswire/ -- RhoVac AB ("RHOVAC") today, 18th May 2022, announces preclinical findings from its collaboration with St. John's Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India. These findings support the hypothesised tissue agnos...
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
STOCKHOLM, Sweden, May 11, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...
RhoVac retains international investment bank as advisor for desired RV001 transaction
STOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,October 11, 2021, that it has retained the services of Stifel Nicolaus Europe Limited ("Stifel"), a global investment bank, as its exclusive financial adviser in connection with ...
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...
Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
STOCKHOLM, July 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onJuly 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac. The safety...
RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021
STOCKHOLM, May 31, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021. Also, all new US clinics hav...
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
STOCKHOLM, April 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,April 21st 2021, that the prestigiousMount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac's clinical phase IIb study, "BRaVac...
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study
STOCKHOLM, March 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,March 8th , 2021, that its clinical phase IIb study, "BRaVac", in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study populatio...
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom
STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in United Kingdom is enroll...
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
LUND, Sweden, Nov. 25, 2020 /PRNewswire/ -- RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate ...
Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer
STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate ...
RhoVac Participates in BIO Europe Digital
LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that it is participating this week in the partnering event BIO Europe 2020 Digital. This week the digital version of the massive pharmaceutical partnering conference BIO Europe is held with participation from RhoVac...
Article on RhoVac's Phase I/II study to be published in November
LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the publication of the article on RhoVac's Phase I/II study is set to be published in November. As previously disclosed, the article elaborating on the results of RhoVac's Phase I/II study in prostate cancer in...
The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study
LUND, Sweden, Oct. 12, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 ("BRaVac"), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitm...
First patient in treatment in RhoVac's clinical phase IIb study in Sweden
STOCKHOLM, Sept. 17, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...
RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board
STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing ProfessorGeorg Hollaender, Action Research Professor and Head of Department at Oxford ...
First patient in treatment in RhoVac's clinical phase IIb study in the USA
STOCKHOLM, Aug. 10, 2020 /PRNewswire/ -- The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, wi...
A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd
STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is published in the June edition of MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for t...
